GlassScriptPhysician profile
Swetha Paduri
NPI 1003478421
$1,635.91
in general payments reported to CMS, 2019-2025
21 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $197 · 2023: $227 · 2024: $853 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.59 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $418.78 | 2022-2025 | Calquence, Enhertu, Imfinzi |
| Genentech USA, INC. | $223.14 | 2022-2025 | Perjeta, Phesgo, Kadcyla |
| Lilly USA, LLC | $151.10 | 2023-2025 | Verzenio, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $129.16 | 2024 | Libtayo |
| Servier Pharmaceuticals LLC | $125.01 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.00 | 2023-2024 | Alunbrig, Ninlaro |
| Tempus Ai, INC | $69.74 | 2024-2025 | Xt Cdx |
| Incyte Corporation | $59.49 | 2024-2025 | Jakafi |
| Amgen INC. | $56.78 | 2022-2024 | Evenity, Prolia |
| Pfizer INC. | $51.06 | 2024-2025 | |
| Seagen INC. | $40.80 | 2023 | Tukysa |
| Merck Sharp & Dohme LLC | $33.90 | 2024 | Keytruda |
| Janssen Biotech, INC. | $31.88 | 2024 | Akeega, Balversa, Erleada |
| Jazz Pharmaceuticals INC. | $27.36 | 2024 | |
| Deciphera Pharmaceuticals INC. | $24.88 | 2024 | Qinlock |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23.91 | 2023 | |
| Novartis Pharmaceuticals Corporation | $23.34 | 2025 | |
| Daiichi Sankyo INC. | $20.86 | 2024 | Enhertu |
| Celgene Corporation | $18.09 | 2025 | Reblozyl |
| Puma Biotechnology, INC. | $17.53 | 2023 | |
| Alexion Pharmaceuticals, INC. | $15.10 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swetha Paduri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.